Skip to content
Triangle logo TriangleGet started
← Full study record

NCT01658878 · OUTCOME

Effective T-Half (T-HALF)

An Immuno-therapy Study to Evaluate the Effectiveness, Safety and Tolerability of Nivolumab or Nivolumab in Combination With Other Agents in Patients With Advanced Liver Cancer · Source last updated 2025-12-24

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

Measure
GEOMETRIC_MEAN
Unit
Hour
Interval / dispersion
Geometric Coefficient of Variation
Time frame
At Cycle 3 Day 1 (Each Cycle = 2 Weeks)

What was measured

Effective half-life is defined as the time it takes for the amount of a drug in the body to decrease by half.

Analysis population: All treated participants in Cohort 1 with baseline and at least 1 post-baseline assessment; uninfected HCC, HCV-infected, and HBV-infected participants reported together as pre-specified.

Groups in this outcome

Cohort 1 Uninfected HCC

Dose Escalation: Uninfected hepatocellular carcinoma (HCC) participants received nivolumab 0.1/0.3/1/3/10 mg/kg every 2 weeks

Cohort 1 HCV Infected

Dose Escalation: Hepatitis C (HCV)-infected participants received nivolumab 0.3/1/3 mg/kg every 2 weeks

Cohort 1 HBV Infected

Dose Escalation: Hepatitis B (HBV)-infected participants received nivolumab 0.1/0.3/1/3 mg/kg every 2 weeks

Group identifiers and denominators belong to this outcome only. They may differ in another outcome or in safety reporting.

Analysis denominator · Participants

GroupSource count
Cohort 1 Uninfected HCC6
Cohort 1 HCV Infected5
Cohort 1 HBV Infected3

Reported measurements

Source class 1
Values in Hour · Interval/dispersion: Geometric Coefficient of Variation
GroupValueSpreadLowerUpperComment
Cohort 1 Uninfected HCC468.0727.65Not reportedNot reportedNot reported
Cohort 1 HCV Infected382.3615.52Not reportedNot reportedNot reported
Cohort 1 HBV Infected406.6015.65Not reportedNot reportedNot reported
Complete source fields
classes
  1. categories
    1. measurements
      1. group Id
        OG000
        spread
        27.65
        value
        468.07
      2. group Id
        OG001
        spread
        15.52
        value
        382.36
      3. group Id
        OG002
        spread
        15.65
        value
        406.60
denoms
  1. counts
    1. group Id
      OG000
      value
      6
    2. group Id
      OG001
      value
      5
    3. group Id
      OG002
      value
      3
    units
    Participants
description
Effective half-life is defined as the time it takes for the amount of a drug in the body to decrease by half.
dispersion Type
Geometric Coefficient of Variation
groups
  1. description
    Dose Escalation: Uninfected hepatocellular carcinoma (HCC) participants received nivolumab 0.1/0.3/1/3/10 mg/kg every 2 weeks
    id
    OG000
    title
    Cohort 1 Uninfected HCC
  2. description
    Dose Escalation: Hepatitis C (HCV)-infected participants received nivolumab 0.3/1/3 mg/kg every 2 weeks
    id
    OG001
    title
    Cohort 1 HCV Infected
  3. description
    Dose Escalation: Hepatitis B (HBV)-infected participants received nivolumab 0.1/0.3/1/3 mg/kg every 2 weeks
    id
    OG002
    title
    Cohort 1 HBV Infected
param Type
GEOMETRIC_MEAN
population Description
All treated participants in Cohort 1 with baseline and at least 1 post-baseline assessment; uninfected HCC, HCV-infected, and HBV-infected participants reported together as pre-specified.
reporting Status
POSTED
time Frame
At Cycle 3 Day 1 (Each Cycle = 2 Weeks)
title
Effective T-Half (T-HALF)
type
SECONDARY
unit Of Measure
Hour

Download exact source JSON → · Snapshot ctgov-results-191f4516d4760045304b24a0

Preserved source evidence · Not medical advice